| abstract |
The invention is directed to the use of glycosaminoglycans for restoring glycocalyx functions or preventing glycocalyx damage. The effectiveness of glycosaminoglycans is directed in all pathologies where glycocalyx damage or this function may be etiologically cause of many pathologies such as: vascular disease, septic states, atherosclerosis syndrome, inflammation states and disease related to ischemia, peritoneal impairment, myocardial infarction, cerebrum- vascular events, alteration of enzymatic glycosylation in diabetes, kidney injury, intestinal disease as ulcerous colitis conditions, pneumoconiosis involving alteration of metabolic activity of pulmonary endothelium. |